Recombinant Mouse Thrombopoietin protein (His Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0678

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse Thrombopoietin was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse Thrombopoietin protein Ser22-Thr356 (Accession# P40226-1) with a His tag at the C-terminus.
• GeneID: 21832
• Accession: P40226-1
• PredictedSize: 36.7 kDa
• SDS-PAGE: 60-85 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Thrombopoietin (TPO) is produced in the liver by both parenchymal cells and sinusoidal endothelial cells, as well as in the kidney by proximal convoluted tubule cells. It is a primary regulator of megakaryocyte development and platelet production in mammals. TPO binds the TPO receptor, activates JAK and STAT pathways, thus stimulating megakaryocyte growth and platelet production. Additionally, as TPO is vital for the maintenance of haematopoietic stem cells, it can truly be described as a pan- haematopoietic cytokine.

References:

1. David J Kuter. et al. (2013). Int J Hematol. 98(1):10-23.
2. Matthew Decker. et al. (2018) Science. 360(6384):106-110.
3. Kenneth Kaushansky. et al. (2006) N Engl J Med. 354(19):2034-45.
4. D Prow. et al. (1998) Oncology (Williston Park). 12(11):1597-604, 1607-8.